My name:	PATIENT ALERT
My contact number: Emergency contact:	GILTERITI ASTELLA
Emergency contact number:	Carry this card with you times, especially when or when you see another.
Name of Haematologist/ Oncologist/Oncoløgy Nurse:	 Please ensure you sho to any doctor, pharmac for any medical treatme visits to the hospital or
Contact number:	 Please contact your do immediately, if you de side effects, in particula listed on this card.
After-hours contact number:	
Name of my Hospital:	
My Hospital contact number:	
	astellas

PATIENT ALERT CARD

GILTERITINIB ASTELLAS

- · Carry this card with you at all times, especially when you travel or when you see another doctor.
- Please ensure you show this card to any doctor, pharmacist or nurse for any medical treatment or at any visits to the hospital or clinic.
- Please contact your doctor immediately, if you develop any side effects, in particular those listed on this card.



4008014/171090

GILTERITINIB ASTELLAS

CRD 40

United Kingdom GB

106 X 115 mm FD

CRD_002


Project 91376

Eq. to: N/A

Proof_01

09 Jul 2025 19:52





IMPORTANT SAFETY INFORMATION FOR PATIENTS

Gilteritinib Astellas may cause serious side effects, including differentiation syndrome.

Differentiation syndrome is a condition that affects your blood cells and may be life-threatening or lead to death if not treated in a timely manner.

Talk to your doctor, pharmacist or nurse **immediately** if you have any of the following symptoms:

- Fever
- Trouble Breathing
- Rash
- · Dizziness or lightheadedness
- Rapid weight gain
- Swelling of your arms or legs

Differentiation syndrome can happen any time during the first 3 months of treatment from as early as 1 day after starting treatment. Getting medical treatment early may stop the problem from becoming more serious.

Your doctor will monitor you, may pause your treatment and/or may give you a medicine to treat your condition.

If you have any further questions about your treatment, please contact your doctor.

IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS

- This patient is being treated with Gilteritinib Astellas, which can cause differentiation syndrome.
- Symptoms include fever, dyspnoea, pleural effusion, pericardial effusion, pulmonary oedema, hypotension, rapid weight gain, peripheral oedema, rash, and renal dysfunction.
- If differentiation syndrome is suspected, corticosteroid therapy should be initiated along with hemodynamic monitoring until symptom resolution.
- If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, Gilteritinib Astellas should be interrupted until signs and symptoms are no longer severe.

Please contact the patient's Haematologist/Oncologist for more information and consult the Product Information for gilteritinib available at www.medicines.org.uk.